Among 69,221 propensity-matched patients with IBD, those who had received a GLP-1 RA had a 5-year colorectal cancer incidence of 0.2% compared with 0.42% in non-GLP-1 RA users (OR, 0.49), corresponding to a 51% reduction in odds of developing colorectal cancer
Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ (2009) JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis
In addition, challenges like individual tolerability and competition from dual agonists, such as Eli Lillys tirzepatide, also demand further optimization [3537]
It does not reduce overall caloric drive, lower hunger signals, or produce the nausea and food aversion that GLP-1 medications often cause